Pill with imprint TV 9702 is Yellow, Round and has been identified as Carbidopa and Levodopa 25 mg / 100 mg. It is supplied by Teva Pharmaceuticals USA, Inc. Carbidopa/levodopa is used in the treatment of Parkinson's Disease; Neuroleptic Malignant Syndrome; GTP-CH Deficiency and belongs to the drug class dopaminergic antiparkinsonism agents.

2021年1月1日 · Carbidopa and levodopa tablets are indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or ... Nonselective monoamine oxidase (MAO) inhibitors are contraindicated for use with carbidopa and levodopa.

2021年11月16日 · Sinemet (carbidopa / levodopa) is a combination medication made up of carbidopa and levodopa. It's one of the first-choice options for Parkinson's disease (PD) to relieve symptoms, such as shakiness and slowed movement.

This yellow round pill with imprint TV 9702 on it has been identified as: Carbidopa/levodopa 25 mg / 100 mg. This medicine is known as carbidopa/levodopa. It is available as a prescription only …

2024年8月20日 · Carbidopa/levodopa is commonly used to treat Parkinson’s disease, a condition that affects the part of your brain that controls your movements. It may also be used to treat conditions with...

2025年2月4日 · Carbidopa and levodopa may be used alone or in combination with other medication to treat symptoms of Parkinson's disease, such as stiffness or tremors in adults. Carbidopa and levodopa is also used in adults to treat Parkinson's disease caused by infection, carbon monoxide poisoning or manganese intoxication.

Pill Identifier results for "9702". Search by imprint, shape, color or drug name.

Product Details Strength 25 mg/100 mg Imprint code TV/9702 Description Round, Mottled Yellow Rating AB

2025年3月8日 · 25 mg/100 mg — Each yellow, mottled, round tablet imprinted with ‘TV’ on one side and ‘9702’on the other side contains 25 mg of carbidopa, USP and 100 mg of levodopa, USP and is supplied in bottles of 100 (NDC 0093-9702-01), …

2022年12月13日 · Carbidopa and levodopa tablets are indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or ... Nonselective monoamine oxidase (MAO) inhibitors are contraindicated for use with carbidopa and levodopa tablets.